Skip to main content
    1. Home

    • UCB Medicines: Clinical Studies and Scientific Research Publication

    Publications

    This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

    Select product(s):
    Select topic(s):
    Phase:

    *Includes seizure clusters and acute or prolonged seizures

    164 result(s)

    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials

    Desiree van der Heijde, Deodhar A. Atul, Xenofon Baraliakos et al.  January 17, 2023
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

    Joseph F. Merola, Landewé B.M. Robert, Iain B McInnes et al.  January 07, 2023
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

    Iain B McInnes, Akihiko Asahina, Laura C Coates et al.  January 07, 2023
    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
    View

    Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

    Xenofon Baraliakos, Deodhar Atul, Dougados Maxime et al.  November 22, 2022
    phase 3

    NAYZILAM® (midazolam) CIV

    Seizure Emergencies
    View

    Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: results of a phase 3, open-label extension trial

    Tze-Chiang Meng, Jerzy P Szaflarski, Linda Chen et al.  November 18, 2022
    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Psoriatic Arthritis
    View

    Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis: Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study 

    Laura C Coates, Iain B McInnes, Joseph F Merola et al.  November 18, 2022
    phase 3

    FINTEPLA® (fenfluramine)

    Lennox-Gastaut Syndrome
    View

    Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study

    Kelly G Knupp, Ingrid E Scheffer, Berten Ceulemans et al.  November 09, 2022
    phase 2

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Efficacy of bimekizumab and other biologics in moderate to severe plaque psoriasis: A systematic literature review and a network meta-analysis.

    Armstrong April, K. Fahrbach, Leonardi Craig et al.  July 07, 2022
    phase 3

    BIMZELX® (bimekizumab-bkzx)

    Plaque Psoriasis
    View

    Bimekizumab safety in patients with moderate to severe plaque psoriasis: Pooled results from phase 2 and phase 3 randomized clinical trials.

    Gordon B. Kenneth, Langley G. Richard, Warren B. Richard et al.  July 01, 2022
    phase 3

    FINTEPLA® (fenfluramine)

    Lennox-Gastaut Syndrome
    View

    Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized clinical trial

    Kelly G Knupp, Ingrid E Scheffer, Berten Ceulemans et al.  May 02, 2022